Solid Tumor Malignancies clinical trials

Explore recruiting solid tumor malignancies clinical trials.

Recruiting solid tumor malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Solid Tumor Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies.

Italy, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Spain, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Solid Tumor Malignancies trials by city

Solid Tumor Malignancies in Toronto Solid Tumor Malignancies in Vancouver Solid Tumor Malignancies in Montreal Solid Tumor Malignancies in Calgary Solid Tumor Malignancies in Edmonton Solid Tumor Malignancies in Ottawa Solid Tumor Malignancies in Winnipeg Solid Tumor Malignancies in Quebec City Solid Tumor Malignancies in Hamilton Solid Tumor Malignancies in Kitchener Solid Tumor Malignancies in London Solid Tumor Malignancies in Halifax Solid Tumor Malignancies in New York Solid Tumor Malignancies in Los Angeles Solid Tumor Malignancies in Chicago Solid Tumor Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease